These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 16026227)

  • 41. [Effects of escitalopram on anxiety symptoms in depression].
    Spadone C
    Encephale; 2002; 28(5 Pt 1):461-5. PubMed ID: 12386549
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Escitalopram and citalopram: the unexpected role of the R-enantiomer].
    Jacquot C; David DJ; Gardier AM; Sánchez C
    Encephale; 2007; 33(2):179-87. PubMed ID: 17675913
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical pharmacology review of escitalopram for the treatment of depression.
    Pastoor D; Gobburu J
    Expert Opin Drug Metab Toxicol; 2014 Jan; 10(1):121-8. PubMed ID: 24289655
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Social anxiety disorder under scrutiny.
    Davidson JR
    Depress Anxiety; 2000; 11(3):93-8. PubMed ID: 10875049
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Generalized anxiety disorder: how to treat, and for how long?
    Lam RW
    Int J Psychiatry Clin Pract; 2006; 10 Suppl 1():10-5. PubMed ID: 24931538
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Escitalopram for the treatment of GAD: efficacy across different subgroups and outcomes.
    Stein DJ; Andersen HF; Goodman WK
    Ann Clin Psychiatry; 2005; 17(2):71-5. PubMed ID: 16075659
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vivo neuroimaging correlates of the efficacy of paroxetine in the treatment of mood and anxiety disorders.
    Kilts C
    Psychopharmacol Bull; 2003; 37 Suppl 1():19-28. PubMed ID: 14566198
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Escitalopram-induced word finding difficulty.
    Yang HM; Lee WK; Chang SW; Chiu NM; Huang JH
    Gen Hosp Psychiatry; 2013; 35(1):103.e5-6. PubMed ID: 22632927
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Low-dose tiagabine effectiveness in anxiety disorders.
    Schaller JL; Thomas J; Rawlings D
    MedGenMed; 2004 Sep; 6(3):8. PubMed ID: 15520630
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Escitalopram versus citalopram: the surprising role of the R-enantiomer.
    Sánchez C; Bøgesø KP; Ebert B; Reines EH; Braestrup C
    Psychopharmacology (Berl); 2004 Jul; 174(2):163-76. PubMed ID: 15160261
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram.
    Kasper S; Sacher J; Klein N; Mossaheb N; Attarbaschi-Steiner T; Lanzenberger R; Spindelegger C; Asenbaum S; Holik A; Dudczak R
    Int Clin Psychopharmacol; 2009 May; 24(3):119-25. PubMed ID: 19367152
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Escitalopram: efficacy and tolerability in the treatment of depression.
    Baldwin DS
    Hosp Med; 2002 Nov; 63(11):668-71. PubMed ID: 12474611
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram.
    Stein DJ; Baldwin DS; Dolberg OT; Despiegel N; Bandelow B
    J Clin Psychiatry; 2006 Nov; 67(11):1741-6. PubMed ID: 17196054
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New developments in pharmacotherapy of pediatric anxiety disorders.
    Garland EJ
    Expert Rev Neurother; 2002 Mar; 2(2):203-11. PubMed ID: 19811001
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Escitalopram for psychogenic nausea and vomiting: a report of two cases.
    Hsu WY; Huang SS; Chiu NY
    J Formos Med Assoc; 2011 Jan; 110(1):62-6. PubMed ID: 21316015
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Pharmacotherapy of anxiety disorders].
    Bitter I
    Orv Hetil; 1995 Nov; 136(45):2435-9. PubMed ID: 8524548
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy, effectiveness and efficiency of escitalopram in the treatment of major depressive and anxiety disorders.
    Lam RW; Annemans L
    Expert Rev Pharmacoecon Outcomes Res; 2007 Dec; 7(6):559-76. PubMed ID: 20528319
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment of social anxiety disorder with citalopram.
    Varia IM; Cloutier CA; Doraiswamy PM
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Jan; 26(1):205-8. PubMed ID: 11853114
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evidence-based treatment of anxiety disorders.
    Stein DJ
    Int J Psychiatry Clin Pract; 2006; 10 Suppl 1():16-21. PubMed ID: 24931539
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anxiety disorders: under-diagnosed and insufficiently treated.
    Kasper S
    Int J Psychiatry Clin Pract; 2006; 10 Suppl 1():3-9. PubMed ID: 24931537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.